RAMP1 and migraine disorder: The transdermal application of ZOL transdermal patches (TPFsp60/6−1:1) further significantly reduced RAMP-1 and NPTX-2 mean gene expression in rats’ brains by 31.3 and 50%, respectively, compared to the untreated rats with induced migraine, presumably due to enhanced brain delivery and accessibility to target molecules and transcription factors that may regulate these genes.